Lauren Dembeck is a journalist and writer who specializes in medical and healthcare topics. With a focus on hematology, infectious diseases, and oncology, Lauren's work has appeared in various publications including Hematology Advisor, Infectious Disease Advisor, and Oncology Nurse Advisor. She is dedicated to providing accurate and up-to-date information to healthcare professionals and the general public.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lauren Dembeck's articles predominantly cite data related to medical research, hematology, cancer treatment, and blood disorders. She appears to focus on scientific themes within the healthcare and pharmaceutical sector. Given her reliance on data-backed information, she may be interested in receiving pitches from researchers or professionals with access to new and significant datasets or those who can provide expert analysis of existing ones.
Lauren appears to have a broad international scope rather than a specific geographic focus. Her coverage seems centered around developments in medical research and treatments globally without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lauren Dembeck
Addition of the histone deacetylase inhibitor romidepsin (Ro) to a cyclophosphamide, doxorubicin, vincristine, and prednisone backbone (CHOP) did not increase efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma (PTCL), according to research published in the Journal of Clinical Oncology.
By: Lauren Dembeck
Researchers sought to determine whether HSCT is an important treatment option for patients with Ph+ ALL if only imatinib and second-generation TKIs are available and affordable.
By: Lauren Dembeck
A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
By: Lauren Dembeck
Researchers sought to determine whether a sequential treatment program comprising VRD induction, ASCT, KRD consolidation, and lenalidomide maintenance is feasible in patients with newly diagnosed multiple myeloma.
By: Lauren Dembeck
Researchers estimated hemoglobin thresholds to define anemia in individuals aged 6 months to 65 years and found they are relatively consistent across diverse populations, according to findings published in The Lancet Haematology
By: Lauren Dembeck
Young adult cancer survivors have a meaningful chance of pregnancy following allogeneic hematopoietic cell transplantation (alloHCT), according to research published in Blood.
By: Lauren Dembeck
Consolidation with allogeneic stem cell transplantation (alloSCT) or autologous SCT (autoSCT) leads to comparable long-term survival outcomes in younger, transplant-eligible patients with peripheral T-cell lymphoma (PTCL), according to research published in the Journal of Clinical Oncology.
By: Lauren Dembeck
Bridging radiotherapy (BRT) for chemotherapy-refractory central nervous system lymphoma (CNSL) results in rapid cytoreduction before chimeric antigen receptor (CAR) T-cell therapy and is associated with favorable CNS response and CAR-T therapy–associated neurotoxicity profiles, according to research published in Blood Advances.
By: Lauren Dembeck
Researchers have confirmed previous findings and further characterized patterns of progression to multiple myeloma in patients with smoldering multiple myeloma (SMM). 1 The study was published in Blood Cancer Journal.
By: Lauren Dembeck
In patients with myelofibrosis (MF) and thrombocytopenia, achievement of spleen volume reduction (SVR) with pacritinib, but not best available therapy (BAT), was associated with a significant overall survival (OS) benefit, according to research published in European Journal of Haematology.
(833) 317-6278 